The Prosigna 50-gene profile and responsiveness to adjuvant anthracycline-based chemotherapy in high-risk breast cancer patients

The DBCG89D trial randomized high-risk early breast cancer patients to adjuvant CMF (cyclophosphamide, methotrexate and fluorouracil) or CEF (cyclophosphamide, epirubicin and fluorouracil). Prosigna assays were performed by researchers with no access to clinical data. Time to distant recurrence (DR)...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:NPJ Breast Cancer
Main Authors: Jensen, Maj-Britt, Lænkholm, Anne-Vibeke, Balslev, Eva, Buckingham, Wesley, Ferree, Sean, Glavicic, Vesna, Dupont Jensen, Jeanette, Søegaard Knoop, Ann, Mouridsen, Henning T., Nielsen, Dorte, Nielsen, Torsten O., Ejlertsen, Bent
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group UK 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7044229/
https://ncbi.nlm.nih.gov/pubmed/32140564
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41523-020-0148-0
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados